GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mereo BioPharma Group PLC (NAS:MREO) » Definitions » Loans Receivable

Mereo BioPharma Group (Mereo BioPharma Group) Loans Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Mereo BioPharma Group Loans Receivable?

Mereo BioPharma Group's Loans Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


Mereo BioPharma Group Loans Receivable Historical Data

The historical data trend for Mereo BioPharma Group's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mereo BioPharma Group Loans Receivable Chart

Mereo BioPharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Mereo BioPharma Group Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Mereo BioPharma Group Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Mereo BioPharma Group Loans Receivable Related Terms

Thank you for viewing the detailed overview of Mereo BioPharma Group's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Mereo BioPharma Group (Mereo BioPharma Group) Business Description

Traded in Other Exchanges
Address
One Cavendish Place, 4th Floor, London, GBR, W1G 0QF
Mereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod.

Mereo BioPharma Group (Mereo BioPharma Group) Headlines

From GuruFocus

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

By sperokesalga sperokesalga 05-05-2023

Mereo BioPharma to Present at the Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-31-2023